PT  - JOURNAL ARTICLE
AU  - Mark Danta
TI  - Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection
AID  - 10.1136/ebmed-2011-100469
DP  - 2012 Oct 01
TA  - Evidence Based Medicine
PG  - 143--144
VI  - 17
IP  - 5
4099  - http://ebm.bmj.com/content/17/5/143.short
4100  - http://ebm.bmj.com/content/17/5/143.full
SO  - Evid Based Med2012 Oct 01; 17